Smithkline Beecham Corporation

Smithkline Beegham P.l.c.

Neil Upton

John M Evans

Mervyn Thompson

Wai Ngor Chan

Robert N Willette

Geoffrey Stemp

Guy Anthony Kennett

Jonathan Alexander Terrett

Andrew Parsons

Saraswati R Patel

James Joseph Hagan

Martin Ian Smith

Kuok Keong Vong

David Piper

Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.

Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72

Benzopyran derivatives and analogs are disclosed as useful for the treatment and/or prophylaxis of neuralgia, trigeminal neuralgia, neuropathic pain, dental pain and cancer pain.

Use of benzopyranols to treat neurological disorders

A compound of formula (I) or pharmaceutically acceptable salt thereof: ##STR1## wherein either Y is N and R.sub.2 is hydrogen, or Y is C--R.sub.1 ; where either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of hydrogen, C.sub.3-8 cycloalkyl, C.sub.1-6 alkyl optionally interrupted by oxygen or substituted by hydroxy, C.sub.1-6 alkoxy or substituted arminocarbonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkoxy, nitro, cyano, halo, trifluoromethyl, CF.sub.3 S, or a group CF.sub.3 --A--, or a group CF.sub.2 H--A'--, trifluoromethoxy, C.sub.1-6 alkylsulphinyl, perfluoro C.sub.2-6 alkylsulphonyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, phosphono, arylcarbonyloxy, heteroarylcarbonyloxy, arylsulphinyl, heteroarylsulphinyl, arylsulphonyl, heteroarylsulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, 1-mercapto C.sub.2-7 alkyl, formyl, or aminosulphinyl, aminosulphonyl or aminocarbonyl, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino, C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl)NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C.sub.1-6 alkyl or by C.sub.2-7 alkanoyl; or R.sub.1 and R.sub.2 together are --(CH.sub.2).sub.4 -- or --CH.dbd.CH--CH.dbd.CH--, or form an optionally substituted triazole or oxadiazole ring; R.sub.3 to R.sub.9 represent various substituent groups; and X is oxygen or NR.sub.10 where R.sub.10 is hydrogen or C.sub.1-6 alkyl.

Pharmaceutical composition containing bicyclic type compounds

Bicyclic compounds with pharmaceutical activity

Benzopyran-3-ols having anxiolytic and anticonvulsant activity are claimed.

Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant

4-(Fluorobenzoylamino)-3,4-dihydro-benzopyran derivatives are disclosed to possess anxiolytic and anti-convulsant activities.

Growing community of inventors

Harlow, United Kingdom

Neil Upton